For example, in a study exploring the benefits of insulin plus pioglitazone in poorly controlled T2D patients, this combination therapy not only improved blood glucose levels and reduced daily insulin dosages, but also had a positive effect on lipid level control, suggesting that the co-administration of insulin and pioglitazone could improve the therapeutic effects of diabetes patients in multiple aspects (91). This evidence concerns the gene INS and type 2 diabetes mellitus.